XML 52 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Research and Development Agreements (Tables)
9 Months Ended
Sep. 30, 2013
Agreement With Gsk
 
Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues recognized under our agreement with GSK (in thousands):

 

 

Three months Ended
September 30,

 

  

Nine months Ended
September 30,

 

 

2013

 

  

2012

 

  

2013

 

  

2012

 

Initial payment             

$

  357

 

 

$

  357

 

 

$

  1,071

 

 

$

  1,071

 

 

Astra Zeneca
 
Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands):

 

 

Three Months Ended
September 30,

 

  

Nine Months Ended
September 30,

 

 

2013

 

  

2012

 

  

2013

 

  

2012

 

Initial payment             

$

  180

  

  

$

  180

  

  

$

  540

  

  

$

  540

  

Performance of research activities             

 

  573

  

  

 

  513

  

  

 

  1,738

  

  

 

  1,991

  

Total             

$

  753

  

  

$

  693

  

  

$

  2,278

  

  

$

  2,531

  

 

National Institutes of Health
 
Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

 

 

Three Months Ended
September 30,

 

  

Nine Months Ended
September 30,

 

 

2013

 

  

2012

 

  

2013

 

  

2012

 

NIAID contracts             

$

  1,465

  

  

$

  1,100

  

  

$

  3,125

  

  

$

  2,840

  

All other NIH contracts             

 

  235

  

  

 

  119

  

  

 

  730

  

  

 

  348

  

Total grant revenue             

$

  1,700

  

  

$

  1,219

  

  

$

  3,855

  

  

$

  3,188